Novozymes (CPSE:NSIS B) Could Be 13% Undervalued After €600 Million Patalganga Expansion

Expansion in Patalganga puts Novozymes under the spotlight

Novozymes (CPSE:NSIS B) has come into focus after Novonesis announced a €600 million plan to expand its Patalganga site, with the aim of increasing biosolutions capacity for customers across high growth markets.

For context, Novozymes shares last closed at DKK429.4. A 90-day share price return of 13.00% points to building momentum, even though the 1-year total shareholder return of 8.50% and the 5-year total shareholder return, which declined 4.15%, tell a more mixed long-term story.

Scan other biosolutions and materials players riding similar themes by reviewing the hand picked 616 high quality undiscovered gems that sit at the crossroads of capacity expansion and long run demand for sustainability focused products.

The Patalganga spend and a 37.0% intrinsic discount suggest upside on paper, while a 5-year return that declined 4.15% hints at market hesitation. Is Novozymes cheap for a reason, or is this cautious pricing a misjudgment?

Most Popular Narrative: 13% Undervalued

Against a last close of DKK429.4, the most followed narrative on Novozymes points to a fair value of DKK491.93, suggesting the market price trails the story analysts are building around the business.

Strategic build out of commercial and technical presence in high growth emerging markets, combined with a robust innovation pipeline and cross selling synergies from acquisitions such as Feed Enzyme Alliance, should sustain above market volume growth, support the 6% to 9% long term organic growth ambition and enhance earnings resilience.

See why 5 investors see Novozymes as 13% undervalued .

Result: Fair Value of DKK491.93 (UNDERVALUED)

Still, Novozymes faces currency pressure on earnings and the risk that heavy emerging market investment delivers slower uptake than analysts currently build into their models.

Find out about the key risks to this Novozymes narrative .

Another View on Novozymes' Valuation

The earlier fair value of DKK491.93 presents Novozymes as undervalued based on future cash flows. The preferred P/E comparison tells a different story. At 42.4x versus a fair ratio of 28.8x, and against European Chemicals at 17.7x and peers at 30.7x, the stock appears expensive. This raises the question of whether the market is overpaying for quality or pricing in the growth narrative early.

For a closer look at how this earnings multiple could change as expectations shift, review See what the numbers say about this price — find out in our valuation breakdown. .